Researchers at Weill Cornell Medicine have mapped the structural changes of the Parkinson's protein LRRK2, revealing how mutations lead to hyperactivity. This breakthrough guides the development of targeted therapies.
USC scientists identified compounds that target cPLA2, an enzyme linked to Alzheimer's inflammation, especially in APOE4 gene carriers. This offers a potential new therapeutic approach for the disease.
RiboNN, a new AI model, predicts mRNA translation efficiency, enhancing protein production for therapies and vaccines. Developed by UT Austin & Sanofi, it accelerates drug discovery by reducing trial-and-error.
Scientists extracted asperigimycins from Aspergillus flavus, a fungus, showing potential against leukemia cells. Bioengineered fungal RiPPs disrupt cancer cell division with high specificity, equalling FDA drugs.
